Table 4.

Effect of AEPN on pancreatic markers of oxidative stress.

Groups	TBARS	GSH	SOD	CAT
	(nmole MDA/mg protein)	(nmole/mg protein)	(units/mg protein)	(nmole H2O2/min /mg protein)
I	15.15 ± 0.14	12.06 ± 0.62	18.15 ± 0.88	50.33 ± 1.14
II	95.75 ± 1.91b	3.20 ± 0.22b	6.17 ± 0.55b	18.12 ± 1.34b
III	63.46 ± 1.68b	5.17 ± 0.19b	10.57 ± 0.54b	23.74 ± 1.41b
IV	52.92 ± 1.74a	7.98 ± 0.19a	12.03 ± 0.96a	28.36 ± 1.11b
V	48.97 ± 2.05a	8.43 ± 0.66a	15.01 ± 0.48a	31.85 ± 1.49a
VI	53.95 ± 2.77a	7.44 ± 0.38a	10.17 ± 0.79b	27.74 ± 1.04
VII	58.42 ± 1.28b	7.37 ± 0.49a	11.38 ± 1.35a	26.09 ± 1.24

n = 7, Data are expressed as mean ± S.E.M, ^ap < 0.05 and ^bp ≤ 0.05 are statistical significant differences in comparison with diabetic control and normal control group respectively. Group I-VII are normal control, diabetic control, AEPN (200 mg/kg), AEPN (400 mg/kg), AEPN (800 mg/kg), metformin (180 mg/kg) and glibenclamide (1 mg/kg) group respectively.